The increasing clinical adoption of circulating tumor DNA (ctDNA) analysis provides a minimally invasive approach to real-time tumor monitoring; however, the clinical relevance of plasma-detected PIK3CA mutations—especially in relation to specific molecular subtypes and treatment outcomes—remains insufficiently characterized. The gene discussed is PIK3CA; the disease is neoplasm.